BioTime, Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine is designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines, including tissue banking, cellular therapy, gene therapy and tissue engineering. Through its ESI BIO division, the Company offers human stem cell products and technologies that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. The Company has developed research and clinical grade hES cell lines. The Company’s subsidiary, ES Cell International Pte Ltd (ESI), has developed six hES cell lines.